Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A morphometric signature to identify ductal carcinoma in situ with a low risk of progression.
Sobral-Leite M, Castillo SP, Vonk S, Messal HA, Melillo X, Lam N, de Bruijn B, Hagos YB, van den Bos M, Sanders J, Almekinders M, Visser LL, Groen EJ, Kristel P, Ercan C, Azarang L, van Rheenen J, Hwang ES, Yuan Y; Grand Challenge PRECISION Consortium; Menezes R, Lips EH, Wesseling J. Sobral-Leite M, et al. Among authors: de bruijn b. NPJ Precis Oncol. 2025 Jan 28;9(1):25. doi: 10.1038/s41698-024-00769-6. NPJ Precis Oncol. 2025. PMID: 39875514 Free PMC article.
Artificial intelligence-based morphometric signature to identify ductal carcinoma in situ with low risk of progression to invasive breast cancer.
Sobral-Leite M, Castillo S, Vonk S, Melillo X, Lam N, de Bruijn B, Hagos Y, Sanders J, Almekinders M, Visser L, Groen E, Kristel P, Ercan C, Azarang L, Yuan Y; Grand Challenge PRECISION Consortium; Menezes R, Lips E, Wesseling J. Sobral-Leite M, et al. Among authors: de bruijn b. Res Sq [Preprint]. 2023 Dec 13:rs.3.rs-3639521. doi: 10.21203/rs.3.rs-3639521/v1. Res Sq. 2023. Update in: NPJ Precis Oncol. 2025 Jan 28;9(1):25. doi: 10.1038/s41698-024-00769-6. PMID: 38168198 Free PMC article. Updated. Preprint.
The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.
Bornes L, van Winden LJ, Geurts VCM, de Bruijn B, Azarang L, Lanfermeijer M, Caruso M, Proost N, Boeije M, Lohuis JO, Belthier G, Noguera Delgado E, de Gruil N, Kroep JR, van de Ven M, Menezes R, Wesseling J, Kok M, Linn S, Broeks A, van Rossum HH, Scheele CLGJ, van Rheenen J. Bornes L, et al. Among authors: de bruijn b. Nature. 2025 Jan;637(8044):195-204. doi: 10.1038/s41586-024-08276-1. Epub 2024 Dec 4. Nature. 2025. PMID: 39633046 Free PMC article.
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction.
Vredevoogd DW, Apriamashvili G, Levy PL, Sinha S, Huinen ZR, Visser NL, de Bruijn B, Boshuizen J, van Hal-van Veen SE, Ligtenberg MA, Bleijerveld OB, Lin CP, Díaz-Gómez J, Sánchez SD, Markovits E, Simon Nieto J, van Vliet A, Krijgsman O, Markel G, Besser MJ, Altelaar M, Ruppin E, Peeper DS. Vredevoogd DW, et al. Among authors: de bruijn b. J Immunother Cancer. 2024 Nov 7;12(11):e010145. doi: 10.1136/jitc-2024-010145. J Immunother Cancer. 2024. PMID: 39510795 Free PMC article.
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness.
Lin CP, Levy PL, Alflen A, Apriamashvili G, Ligtenberg MA, Vredevoogd DW, Bleijerveld OB, Alkan F, Malka Y, Hoekman L, Markovits E, George A, Traets JJH, Krijgsman O, van Vliet A, Poźniak J, Pulido-Vicuña CA, de Bruijn B, van Hal-van Veen SE, Boshuizen J, van der Helm PW, Díaz-Gómez J, Warda H, Behrens LM, Mardesic P, Dehni B, Visser NL, Marine JC, Markel G, Faller WJ, Altelaar M, Agami R, Besser MJ, Peeper DS. Lin CP, et al. Among authors: de bruijn b. Cancer Cell. 2024 Apr 8;42(4):623-645.e10. doi: 10.1016/j.ccell.2024.02.016. Epub 2024 Mar 14. Cancer Cell. 2024. PMID: 38490212 Free PMC article.
A double-blind, randomised, placebo-controlled trial comparing intrathecal bupivacaine with bupivacaine plus morphine to reduce delirium in patients with hip fractures-Salmon-Mind trial study protocol.
Teunissen AJW, Koning MV, Liefers WJ, Stap DVD, Roukema G, de Bruijn B, Teunissen CE, Koopman SA. Teunissen AJW, et al. Among authors: de bruijn b. BJA Open. 2023 Jul 20;7:100216. doi: 10.1016/j.bjao.2023.100216. eCollection 2023 Sep. BJA Open. 2023. PMID: 37638088 Free PMC article. Clinical Trial.
An adverse tumor-protective effect of IDO1 inhibition.
Kenski JCN, Huang X, Vredevoogd DW, de Bruijn B, Traets JJH, Ibáñez-Molero S, Schieven SM, van Vliet A, Krijgsman O, Kuilman T, Pozniak J, Loayza-Puch F, Terry AM, Müller J, Logtenberg MEW, de Bruijn M, Levy P, Körner PR, Goding CR, Schumacher TN, Marine JC, Agami R, Peeper DS. Kenski JCN, et al. Among authors: de bruijn b. Cell Rep Med. 2023 Feb 21;4(2):100941. doi: 10.1016/j.xcrm.2023.100941. Cell Rep Med. 2023. PMID: 36812891 Free PMC article.
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS. Boshuizen J, et al. Among authors: de bruijn b. Nat Commun. 2023 Feb 7;14(1):672. doi: 10.1038/s41467-023-35852-2. Nat Commun. 2023. PMID: 36750559 Free PMC article. No abstract available.
50 results